Blue Jet Healthcare Ltd

Financial highlights

• FY25-26 revenue ₹9,473.21m; PAT ₹2,478.16m.
• EBITDA ₹2,941m; gross margin 54%; PAT margin 26%.
• EPS ₹14.29; final dividend ₹1.20 per share proposed.
• QIP raised ₹8,000m; public shareholding 26.85%.
• Company debt-free; liquid assets ~₹350 crore.
• Operating cash flow ₹334 crore for FY2025-26.
• SAP S/4HANA go-live under PROJECT LEAP.

Growth strategy & major investments

• Vizag greenfield: 100 acres; Phase-1 ₹1,000 crore capex.
• Vizag capex long-term up to ₹2,300 crore.
• Mahad backward integration on track to strengthen supply.
• Hyderabad R&D center: 57,240 sq ft; live in H2 FY2026-27.
• Vizag to host complex CMIs and APIs; scale in three segments.
• Raising up to ₹1,000 crore authorized for FY27 expansion.

Capital structure & liquidity

• Authorized capital ₹470m; issued ₹346.93m across 17.346m shares.
• Public shareholding at 26.85%; 8,000m QIP completed.
• No debt; lease liabilities ₹421.84m total.
• Cash & cash equivalents ₹608.57m; balances with banks ₹880.14m.
• Investments: mutual funds ₹2,266.97m; debentures ₹251.85m.
• Total equity ₹13,599.12m; net debt nil.

ESG and sustainability

• About 70% of energy from renewables; ISO 50001 certified.
• ZLD system; 48,827 KL water recycled in FY26.
• GHG: Scope 1 26,166.64; Scope 2 5,971.83 tCO2e; total 32,138.47.
• Scope 3 emissions 49,529.68 tCO2e; first-year tracking.
• EcoVadis Silver; CSR spend ₹44.5m; 100% supplier assessments.
• CSR policy aligned with education, healthcare, skill development.

Governance & risk management

• Board of 8 directors; 4 independent; 3 women on board.
• 6 board meetings; 5 Audit Committee meetings in FY26.
• Statutory auditors: KKC & Associates LLP; proposed reappointment.
• Secretarial audit: MR-3; no qualifications reported.
• Robust Risk Management Committee with formal framework.

Dividend & AGM

• 58th AGM on 21 Sept 2026 via VC/OAVM.
• Final dividend ₹1.20 per share; record date 14 Sept 2026.
• Dividend payable within 30 days post-AGM; TDS as per tax laws.
• Notice & Annual Report accessible on company website.

Market, customers & products

• Product categories: CMIs, high‑intensity sweeteners, pharma intermediates & APIs.
• Two top customers contribute ~40.6% and ~30.5% of revenue.
• Export share high; Norway ₹3,828.81m; France ₹3,354.32m; rest ₹1,292.31m.
• Domestic sales ₹942.73m; exports ₹8,472.80m; R&D services ₹2.70m.

Operations & capacity

• Facilities: Unit I Shahad; Unit II Ambernath; Unit III Mahad; Unit IV Ambernath.
• Installed capacities: 200.60 KL (Unit I), 833.60 KL (Unit II), 141.40 KL (Unit III).
• Plant 6 commissioned at Ambernath (Unit II) with 157.60 KL capacity.
• Vizag expansion adds ~1,000 KL in Phase-1 by FY2028-29.

BRSR scope and assurance

• BRSR for FY2025-26 filed; standalone basis with TÜV India assurance.

Governance & reporting framework

• Board oversees BR/ESG; Senior BR policy official designated for BR policy.

Environmental performance and resource use

• 57% renewable energy share; solar 5.625 MW and wind 3.2 MW.
• Scope 1+2 emissions total 32,138 tCO2e; intensity 0.0000339 tCO2e/INR.
• First-year Scope 3 emissions 49,529.68 tCO2e; PPP intensity 0.000106.
• Zero Liquid Discharge system; treated water reused; CETP discharge per consent.

Social and CSR highlights

• Board female representation 37.5%; KMP female 50%.
• CSR expenditure fully allocated to education, healthcare, elderly care, environment.

AGM Details

• AGM on 21 September 2026 at 11:00 IST via VC/OAVM.
• Deemed venue: registered office address.
• Record date for final dividend: 14 September 2026.

Ordinary resolutions

• Adopt standalone financial statements for year ended 31 March 2026.
• Declare final dividend of ₹1.20 per share for FY 2026.
• Re-appoint Naresh Shah as director retiring by rotation.
• Re-appoint M/s KKC & Associates LLP as Statutory Auditors for second five-year term.
• Auditors' proposed FY2026-27 fees: ₹37 lakhs.

Special resolutions

• Re-appoint Akshay Bansarilal Arora as Whole-Time Director and Executive Chairman for 5 years; remuneration as per statement.
• Re-appoint Shiven A. Arora as Managing Director for 5 years; remuneration as per statement.

Voting mechanics

• E-voting window: Sept 18–20, 2026; results announced within two working days.

Financial Performance

• Turnover: INR293 crores in Q1, up 25% QoQ.
• Gross margin 53%; EBITDA margin 33.5%, up from prior quarter.
• PAT margin 26.7% this quarter; 27.4% prior quarter.
• QIP completed, strengthening balance sheet and financial flexibility.
• Capex plan: approx INR1,000 crores over three years; ~INR250 crores in FY27.
• Invested about INR210 crores in Unit 3, Mahad; INR40 crores more committed.

Operations and Strategy

• Vizag Phase I expansion underway; CM intermediates and HI sweetener pilot in scope.
• Hyderabad R&D center to become operational this month.
• Unit 3 backward integration on-track; commercial contribution expected in H2 FY27.
• Vizag expansion includes securing ~100 acres for long-term growth; multi-chemistry platform.
• EcoVadis Silver Medal; CII Energy Management Award; ~70% energy from renewables.

Projects and Capex

• Vizag Phase I capex ~INR1,000 crores over 3 years.
• Vizag 100 acres secured for long-term expansion.
• Invested about INR210 crores in Mahad Unit 3; INR40 crores more committed.
• FY27 capex guidance ~INR400 crores; next three years ~INR1,000 crores.

Outlook and Guidance

• FY27 to launch 3 Contrast Media candidates; pilot high-intensity sweetener.
• Two LCE opportunities expected to fructify in 2-3 years; diversify PI/API.
• Vizag platform designed for multiple chemistries and customers; long-term growth driver.
• Management remains disciplined; continued visibility improvements across businesses.

Q&A Highlights

• CM revenues to be recognized next quarter due to goods in transit; plant utilization around 70%.
• FY27: launch 3 Contrast Media candidates; pilot high-intensity sweetener.
• No price increases this quarter; raw-material costs offset by rupee devaluation.
• Two LCE opportunities expected to fructify in 2-3 years.
• FY27 capex guidance maintained at about INR400 crores.

Meeting Details

• Date and time: August 03, 2026 at 5:30 PM IST.
• Audience: group of analysts and investors.
• Meeting type and mode: group investor call, virtual conference.
• Organizer: Blue Jet Healthcare Limited.

Participants

• Key company participants: Managing Director; Chief Operating Officer; Chief Financial Officer; Deputy Chief Financial Officer.

Purpose

• To discuss unaudited standalone results for the quarter ended June 30, 2026.

Meeting Details

• Board meeting on August 03, 2026 to consider unaudited standalone Q1 results.

Key Agenda Items

• Approval of unaudited standalone financial results for quarter ended June 30, 2026, with Limited Review Report.

Other Notes

• Trading window closed for 48 hours post declaration of results; reopens August 06, 2026.

EcoVadis Silver Medal

• Announcement date July 20, 2026.
• Awarded Silver Medal for sustainability across Environment, Labor and Human Rights, Ethics, and Sustainable Procurement.
• EcoVadis score 77/100; ranks in the top 15% globally (90th percentile).